Entry |
|
Name |
Briobacept (USAN) |
Formula |
C2910H4542N814O878S24
|
Exact mass |
65706.9083
|
Mol weight |
65747.74
|
Sequence |
DVRRGPRSLR GRDAPAPTPC NPAECFDPLV RHCVACGLLR TPRPKPAGAS SPAPRTALQP QESVGAGAGE AAVDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG (Disulfide bridge: 79-79', 82-82') |
Type |
Peptide |
Efficacy |
Immunosuppressant |
Comment |
Briobacept is a fusion protein consisting of human BR3 [HSA: 115650] [KO: K05151] and human IgG1 Fc.
Treatment of autoimmune disease
|
Target |
|
Pathway |
hsa04060 | Cytokine-cytokine receptor interaction |
|
Brite |
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Tumor necrosis factors
TNFSF13B (BAFF, CD257)
D08877 Briobacept (USAN)
|
Other DBs |
|